Introduction {#S0001}
============

Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-related death worldwide.[@CIT0001] In China, GC ranks second in tumor incidence and mortality.[@CIT0002]--[@CIT0005] In contrast to other East-Asian countries, early detection of GC is infrequent in the Chinese population,[@CIT0006],[@CIT0007] thus over 80% of patients with GC are diagnosed at an advanced stage with poor overall survival (OS).[@CIT0008] Consequently, it is crucial to provide an improved and optimized treatment strategy that can increase the survival of patients with metastatic gastric cancer (mGC).

Current guidelines generally recommend chemotherapy for patients with mGC, and chemotherapy combined with trastuzumab for those whose cancer is human epidermal growth factor receptor 2 (HER-2) positive. Gastrectomy is recommended to alleviate or control tumor-related complications, such as obstruction and bleeding. However, palliative gastrectomy to reduce the tumor burden or potentially prolong survival remains controversial. The phase 3 randomized controlled trial, REGATTA, has failed to demonstrate a survival benefit of gastrectomy followed by chemotherapy using S-1/cisplatin (SP) compared with chemotherapy alone for advanced GC with a single non-curable factor.[@CIT0009] Although this result seems to settle the discussion on palliative gastrectomy, several questions remain. Notably, patients who underwent palliative gastrectomy demonstrated poorer compliance with chemotherapy than those who had chemotherapy alone, and patients with lower third gastric cancer benefitted more from surgery than those with upper third tumors, implying that the timing of surgery and the type of resection provided might considerably influence survival benefit. Moreover, the chemotherapy used in the REGATTA trial was restricted to the combination of oral S-1 80 mg/m^2^ per day on days 1--21 and cisplatin 60 mg/m^2^ on day 8 of every 5-week cycle, and whether other regimens combined with surgery could be beneficial remains unclear. By contrast, many retrospective studies have challenged the conclusion of the REGATTA trial and have demonstrated improved survival following non-curative gastrectomy, among which one study even observed an increase in the median OS (mOS) of 9.8 months in patients who only had peritoneal seeding and received preoperative palliative chemotherapy.[@CIT0010]--[@CIT0018] As such, it remains undetermined as to whether the survival improvement by palliative gastrectomy is dependent on factors related to the surgical performance or the chemotherapy regimen provided.

Thus, the present study aimed to evaluate the survival benefit of palliative gastrectomy plus chemotherapy compared with chemotherapy alone in patients with mild- or asymptomatic mGC, to investigate the prognostic factors related to clinicopathology and treatment, and to optimize the treatment strategy based on real-world data.

Methods {#S0002}
=======

Ethics statement {#S0002-S2001}
----------------

All patients provided written informed consent prior to the retrospective data retrieval from medical records. The study was conducted according to the principles expressed in the Declaration of Helsinki.

Patient and data collection {#S0002-S2002}
---------------------------

Patients diagnosed with gastric adenocarcinoma with synchronously distant metastasis from January 1st, 2006 to December 31st, 2012 in Sun Yat-Sen University Cancer Center (SYSUCC) were included in the study, and their clinicopathological data and radiographic images were reviewed for selection. Primary gastric tumors were diagnosed by endoscopy or surgical histopathology, and distant metastases were diagnosed by computed tomography or ultrasound imaging (or both), or biopsy histopathology. The palliative gastrectomy should be performed in the first-line treatment; however, the diagnosis-to-surgery interval was not limited for inclusion. The exclusion criteria were as follows: (1) Patients younger than 18 or with an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2; (2) patients with non-adenocarcinoma histology; (3) patients for whom it was unknown whether gastrectomy had been performed; (4) patients who have had metastasectomy, local ablation, or hyperthermic intraperitoneal chemoperfusion (HIPEC); (5) patients who did not receive palliative chemotherapy; (6) patients who had emergency gastrectomy to treat tumor-related complications; and (7) patients who received radical gastrectomy after successful conversion therapy. The following clinicopathological data were collected: Age; sex; year of diagnosis; primary tumor location; metastatic sites; tumor pathological type and grade; baseline serum carcinoembryonic antigen (CEA); and treatment information, including gastrectomy and its timing, types of resection and results of lymph node examining, first-line chemotherapy regimens, and cycles of usage. [Figure 1](#F0001){ref-type="fig"} shows the process of patient selection. Patients recruited according to the inclusion and exclusion criteria were then sub-grouped as the SC group (patients receiving palliative gastrectomy plus chemotherapy) and the CO group (patients receiving chemotherapy only), based on the treatment received.Figure 1Flowchart illustrating the case selection process.**Abbreviations:** GC, gastric cancer; SYSUCC, Sun Yat- Sen University Cancer Center; ECOG PS, Eastern Cooperative Oncology Group performance status; HIPEC, hyperthermic intraperitoneal chemoperfusion.

Follow-up data were collected from the follow-up records constructed and renewed by the Department of Follow-up of SYSUCC. Patients who were uncontactable or refused to answer inquiries were regarded as censored.

Data processing {#S0002-S2003}
---------------

CEA was categorized as normal or elevated based on its normal range (0--5.00 ng/mL), as used at our institution. To categorize metastatic lesions, bilateral organ metastases were regarded as one organ involving metastasis; for example, both ovaries with metastases were counted as one organ. Distant (ie, non-regional) metastatic lymph nodes located in multiple regions were also defined as one organ. Chemotherapy regimens were classified into: (1) Fluoropyrimidine (5- fluorouracil, capecitabine, or S-1) plus platinum (cisplatin or oxaliplatin); (2) taxane-based drugs (ie, regimens including paclitaxel and docetaxel); (3) fluoropyrimidine plus irinotecan; (4) fluoropyrimidine monotherapy; and (5) adriamycin-based drugs (ie, regimens including adriamycin and epirubicin). Types of resection were classified as total gastrectomy and partial gastrectomy, and those lacking clear surgical records for the classification, mainly because the surgery was performed in other hospitals, were referred to as "unknown".

Statistical analysis {#S0002-S2004}
--------------------

Comparisons of patient characteristics between the SC and CO groups were performed using the chi-squared and Fisher's exact tests for categorical variables. OS was the primary endpoint of this study, which was defined as the time from the date of histological diagnosis of primary cancer to the date of death or last follow-up. The Kaplan--Meier method, with the log-rank test, were used for survival analysis. Multivariate Cox analysis, involving factors with a *P*-value \<0.100 in the univariate Cox regression analysis, was used to identify independent prognostic factors. Additionally, prognostic factors of the patients in the SC group were investigated. To minimize the effects of confounding factors, the propensity score matching (PSM) method was used to match SC and CO patients in a 1:1 ratio based on the patients' age, sex, year of diagnosis, primary tumor location, numbers of organs involving metastasis, tumor grade, and baseline CEA. The matching process was conducted using the "MatchIt" R package.[@CIT0019] The subsequent survival analyses were based on the matched population. Subgroup analyses to evaluate the survival benefit of palliative gastrectomy were performed in patients with particular metastatic lesions and in those receiving different chemotherapy treatments. We carried out the sensitivity analysis based on patients whose OS exceeded 3 months to eliminate possible bias from a relatively poor prognosis (OS \<3 months) caused by vicious tumor biological behavior, not the treatment itself. All data analyses were performed using SPSS Statistics 22.0 (IBM Corp., Version 22.0, Armonk, NY, USA) and the "MatchIt" R packages (The R Foundation, version 3.4.2). A two-sided *P*-value \<0.05 was considered statistically significant.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

A total of 236 patients were included in the present study. [Table 1](#T0001){ref-type="table"} summarizes the patient characteristics of the study population. There were 80 patients and 156 patients in the SC and CO groups, respectively. The commonly used first-line chemotherapy regimens were fluoropyrimidine plus platinum and taxane-based regimen for both cohorts; however, only 53.0% (n=125) of the patients received more than four cycles of first-line chemotherapy. Patients in the SC group tended to be diagnosed in the earlier years, to have well or moderately differentiated tumors, to have cancer in the lower two thirds of the stomach, and to have metastatic lesions in only one organ, compared with the patients in the CO group. The chemotherapy regimens and the number of agents applied, the route of administration, and the number of treatment cycles were comparable between groups. After being matched using PSM, no significant differences were detected in all the characteristics analyzed, except the proportions of hepatic metastasis and peritoneal metastasis. This implied that patients with hepatic metastasis tended not to receive palliative gastrectomy while those with peritoneal metastasis did. However, given that metastatic lesions could involve more than one organ, there was no clinical significance in obtaining a balanced distribution of metastatic organs.Table 1Demographic and clinicopathological characteristics of the unmatched and matched population by propensity score matching (PSM)CharacteristicsNumber (%)*P*-value ^d^Matched cohort\
*P*-valueAll cohortWith palliative gastrectomyWithout palliative gastrectomy**Age, years**0.7520.862 \<5084 (35.6%)30 (37.5%)54 (34.6%) 50−5966 (28.0%)19 (23.8%)47 (30.1%) 60−6963 (26.7%)22 (27.5%)41 (26.3%) ≥7023 (9.7%)9 (11.3%)14 (9.0%)**Sex**0.3170.607 Male155 (65.7%)56 (70.0%)99 (63.5%) Female81 (34.3%)24 (30.0%)57 (36.5%)**Year of diagnosis**0.0120.499 2006−200852 (22.0%)26 (32.5%)26 (16.7%) 2009−2010104 (44.1%)34 (42.5%)70 (44.9%) 2011−201280 (33.9%)20 (25.0%)60 (38.5%)**Primary tumor location** ^a^0.0330.164 Upper third150 (63.6%)42 (52.5%)108 (69.2%) Middle third49 (20.8%)22 (27.5%)27 (17.3%) Lower third28 (11.9%)14 (17.5%)14 (9.0%) NOS9 (3.8%)2 (2.5%)7 (4.5%)**Metastatic site**^b^ Liver72 (30.5%)13 (16.3%)59 (37.8%)0.0010.004 Lung18 (7.6%)3 (3.8%)15 (9.6%)0.1080.118 Ovary3 (1.3%)1 (1.3%)2 (1.3%)0.9830.316 Peritoneal implantation111 (47.0%)47 (58.8%)64 (41.0%)0.0100.007 Distal lymph node93 (39.4%)27 (33.8%)66 (42.3%)0.2030.413**Number of organs involving metastasis**0.0480.856 One157 (66.5%)60 (75.0%)97 (62.2%) More than one79 (33.5%)20 (25.0%)59 (37.8%)**Pathology type**0.2120.126 Adenocarcinoma, NOS214 (90.7%)70 (87.5%)144 (92.3%) Mucinous adenocarcinoma6 (2.5%)4 (5.0%)2 (1.3%) Signet ring cell carcinoma16 (6.8%)6 (7.5%)10 (6.4%)**Tumor Grade**0.0410.522 G1/G2108 (45.8%)44 (55.0%)64 (41.0%) G3/G4128 (54.2%)36 (45.0%)92 (59.0%)**Baseline CEA**0.2770.265 Normal range130 (55.1%)48 (60.0%)82 (52.6%) High106 (44.9%)32 (40.0%)74 (47.4%)**Treatment factorsChemotherapy regimens**0.6620.378 Fluoropyrimidine plus Platinum95 (40.3%)29 (36.3%)66 (42.3%) Taxane-based drugs104 (44.1%)36 (45.0%)68 (43.6%) Fluoropyrimidine plus Irinotecan5 (2.1%)1 (1.3%)4 (2.6%) Fluoropyrimidine28 (11.9%)12 (15.0%)16 (10.3%) Adriamycin-based drugs4 (1.7%)2 (2.5%)2 (1.3%)**Number of chemotherapy agents**0.2860.260 One30 (12.7%)14 (17.5%)16 (10.3%) Two187 (79.2%)60 (75.0%)127 (81.4%) Three19 (8.1%)6 (7.5%)13 (8.3%)**Route of medication**0.3690.197 Oral intake144 (61.0%)52 (65.0%)92 (59.0%) Intravenous only92 (39.0%)28 (35.0%)64 (41.0%)**Cycles of chemotherapy**0.1210.425 ≤4 cycles111 (47.0%)32 (40.0%)79 (50.6%) \>4 cycles125 (53.0%)48 (60.0%)77 (49.4%)**Palliative gastrectomy** Yes80 (33.9%)80 (100.0%)0 (0.0%) No156 (66.1%)0 (0.0%)156 (100.0%)**Timing of surgery** Surgery followed by chemotherapy73 (91.3%)  Median cycles of chemotherapy after surgery (Range)5 (1.0−12.0) Chemotherapy followed by surgery7 (8.8%)  Median cycles of chemotherapy before surgery (Range)4.0 (2.0−6.0)  Median cycles of chemotherapy after surgery (Range)2.0 (0.0−6.0)**Types of resection** Total gastrectomy16 (20.0%) Partial gastrectomy27 (33.8%) Unknown37 (46.3%)**Number of lymph nodes retrieved and examined** ≤1515 (18.8%) \>1565 (81.3%)**Number of positive lymph nodes (mean ± SD)**12.16±9.30**Ratio of positive lymph nodes to total lymph nodes examined** ^c^0.54±0.27 \<0.5540 (50.0%) ≥0.5540 (50.0%)[^2]

Survival analysis {#S0003-S2002}
-----------------

The mOS of the SC group was significantly longer than that of the CO group (17.0 months *vs* 12.0 months, *P*=0.038) ([Figure 2A](#F0002){ref-type="fig"}). Palliative gastrectomy also demonstrated significantly prolonged mOS in the matched population (17.0 months *vs* 13.0 months, *P*=0.017) ([Figure 2B](#F0002){ref-type="fig"}). In the multivariate analysis, after adjustment for sex, age at diagnosis, year of diagnosis, primary tumor location, and tumor grade, palliative gastrectomy (hazard ratio (HR) =0.68 \[95% confidence interval (CI): 0.49−0.95\], *P*=0.023; matched HR =0.64 \[95% CI: 0.44−0.94\], *P*=0.021) was proved to be associated with better survival.Figure 2Kaplan--Meier survival curves of the patients who received palliative gastrectomy plus chemotherapy (SC group) and those who received chemotherapy only (CO group) before (**A**) and after (**B**) the propensity score matching.

Subgroup analysis of patients with different metastatic sites and chemotherapy regimens {#S0003-S2003}
---------------------------------------------------------------------------------------

[Figure 3](#F0003){ref-type="fig"} demonstrates the survival benefit of SC as compared to CO in particular subgroups of patients. Among the patients whose metastatic lesions were limited to a single organ, palliative gastrectomy was observed to robustly improve their mOS (HR =0.62 \[95% CI, 0.42−0.92\], *P*=0.016). In terms of chemotherapy, a prolonged survival advantage was obtained from gastrectomy in patients who received taxane-based chemotherapy (HR =0.52 \[95% CI, 0.31−0.86\], *P*=0.011) rather than fluoropyrimidine plus platinum (HR =0.76 \[95% CI, 0.43−1.33\], *P*=0.330).Figure 3A forest plot evaluating the survival benefit of palliative gastrectomy plus chemotherapy (SC) versus chemotherapy only (CO) in the subsets of patients with specific metastatic lesions and chemotherapy regimens.

Surgical factors that favored a prolonged survival among SC patients {#S0003-S2004}
--------------------------------------------------------------------

The analyses took into consideration variables associated with surgery, including the timing of surgery, the type of resection, the number of lymph nodes examined, and the ratio of positive lymph nodes to total lymph nodes examined, in addition to patient characteristics ([Table 2](#T0002){ref-type="table"}). The type of resection was found to be independently associated with survival (*P*=0.026). Poorer survival was observed in patients who underwent total gastrectomy compared with patients who underwent other types of gastrectomy. Nevertheless, the timing of surgery (before or after chemotherapy started) and the number of retrieved lymph nodes were found to have no significant influence on survival. Moreover, in the univariate Cox analysis, a high ratio (≥0.55) of positive lymph nodes to total lymph nodes examined was significantly associated with poorer survival (*P*=0.024), but was not an independent prognostic factor in the multivariate analysis (*P*=0.076).Table 2Results of the univariate and multivariate survival analysis by Cox regression of the patients who received gastrectomy plus chemotherapy (SC)VariableUnivariable Cox analysisHR (95% CI)*P*-value**Age, years** \<50Reference0.527 50−591.17 (0.58, 2.36) 60−691.31 (0.66, 2.61) ≥701.90 (0.80, 4.49)**Sex** MaleReference0.397 Female0.77 (0.43, 1.40)**Year of diagnosis** 2006−2008Reference0.615 2009−20101.21 (0.65, 2.26) 2011−20120.87 (0.42, 1.81)**Primary tumor location** Upper one thirdReference0.101 Middle one third0.53 (0.27, 1.06) Lower one third0.89 (0.45, 1.76) NOS3.01 (0.71, 12.86)**Number of organs involving metastasis** OneReference0.428 More than one1.28 (0.70, 2.35)**Pathology type** Adenocarcinoma, NOSReference0.890 Mucinous adenocarcinoma0.82 (0.29, 2.28) Signet ring cell carcinoma1.13 (0.44, 2.86)**Tumor Grade** G1/G2Reference0.188 G3/G41.45 (0.84, 2.51)**CEA** Normal rangeReference0.313 High1.32 (0.77, 2.26)**Surgery timing** Surgery firstReference0.638 Chemotherapy first0.80 (0.32, 2.02)**Resection method** Total gastrectomyReference0.047 Partial gastrectomy0.40 (0.19, 0.85) Unknown0.48 (0.24, 0.97)**Number of lymph nodes retrieved and examined** ≤15Reference0.465 \>150.79 (0.41, 1.50)**Ratio of positive lymph nodes to total lymph nodes examined** \<0.55Reference0.024 ≥0.551.85 (1.08, 3.16)**Chemotherapy regimens** Fluoropyrimidine plus PlatinumReference0.135 Taxane-based drugs1.19 (0.65, 2.18) Fluoropyrimidine plus IrinotecanUnmeasurable ^a^ Fluoropyrimidine2.70 (1.25, 5.82) Adriamycin-based drugs1.72 (0.40, 7.48)**Multivariable Cox analysisResection method** Total gastrectomyReference0.026 Partial gastrectomy0.34 (0.16, 0.73) Unknown0.43 (0.21, 0.88)[^3]

Sensitivity analysis {#S0003-S2005}
--------------------

After excluding 45 patients with OS ≤3 months, the efficacy of SC was re-evaluated and similar results were obtained. The mOS of the SC group remained significantly longer than that in the CO group (19 months \[95% CI, 15.28−22.72\] *vs* 13 months \[95% CI, 10.88−15.12\], *P*=0.033). In the multivariate analysis, SC (HR =0.68 \[95% CI, 0.47−0.97\], *P*=0.034) remained the superior regimen, demonstrating more favorable survival.

Discussion {#S0004}
==========

In patients with mGC, survival prolongation by palliative gastrectomy is still controversial. In the present study, based on real-world data, we aimed to evaluate the survival benefit of palliative gastrectomy plus chemotherapy compared with chemotherapy alone, to investigate treatment factors that favored better survival, and to develop optimal multi-disciplinary treatment.

The results of the present study were consistent with previous retrospective studies,[@CIT0011],[@CIT0013]--[@CIT0017],[@CIT0020],[@CIT0021] in that we demonstrated that patients who received palliative gastrectomy plus chemotherapy had a longer OS as compared with those who received chemotherapy only. A meta-analysis involving 19 non-randomized studies and comprising 2,911 patients observed a possible survival benefit of gastrectomy compared with non-surgical strategies for stage IV GC .[@CIT0017] Other studies analyzed factors that favored the beneficial effects of gastrectomy to narrow down the potential surgical candidates, and to optimize clinical treatment. Hsu et al found that younger age, better preoperative nutritional status, less nodal involvement, and postoperative chemotherapy could independently prolong the survival of patients who received palliative gastrectomy.[@CIT0020] A previous study from our group showed that patients with GC with peritoneal seeding could benefit from palliative chemotherapy followed by gastrectomy. That study also showed that margin-free gastrectomy and more than four cycles of palliative chemotherapy were independent favorable prognostic factors.[@CIT0011] In the present study, SC was found to be associated with better survival, and subgroup analyses for patients with single organ metastasis and patients with peritoneal seedings confirmed the survival improvement resulting from palliative gastrectomy.

To the best of our knowledge, this is the first study to investigate the survival benefit of palliative gastrectomy taking treatment factors (including surgical performance and chemotherapy medication) into consideration. The REGATTA trial strictly limited the chemotherapy medication and dosage, thus its external validation for patients receiving various regimens with different self-suitable dosages should be doubted. For this reason, we used real-world data and further carried out subgroup survival analyses stratified by the chemotherapy regimens. The most commonly accepted first-line chemotherapy regimen as the primary recommendation in China is fluoropyrimidine (5-FU or capecitabine or S-1) plus platinum (cisplatin or oxaliplatin).[@CIT0022]--[@CIT0024] Taxane-based regimens are also adopted as first-line chemotherapy; however, a high incidence of intolerance of taxane-based duplexes or triplexes has retarded their clinical application.[@CIT0025]--[@CIT0027] In the subgroup analysis, a survival advantage was derived from gastrectomy in patients receiving taxane-based chemotherapy, whereas patients treated with fluoropyrimidine plus platinum might not gain a survival benefit from gastrectomy. The chemotherapy-regimen-dependent feature may be attributed to the negative conclusion of the REGATTA trial which used SP for postoperative chemotherapy. The present study preliminarily indicated that specific chemotherapy regimens, such as taxane-based chemotherapy, were suitable for combination with palliative gastrectomy; however, further corroborative evidence is required.

For the patients in the SC group, how to maximize benefit from surgery was explored and questions from the REGATTA trial about the timing and types of surgery were also investigated. In the present study, patients who underwent partial gastrectomy had better survival compared with those who underwent total gastrectomy, probably because of better organ function-preservation.[@CIT0028] The timing of palliative surgery in relation to chemotherapy was not associated with survival according to our analysis. However, several possible advantages of preoperative chemotherapy were reported in previous studies, including the chance of achieving conversing purpose for curative resection and better treatment compliance compared with postoperative chemotherapy.[@CIT0029] For the extent of lymphadenectomy, the number of lymph nodes retrieved was not a prognostic factor, which suggested that D2 lymphadenectomy might not be meaningful and necessary in the palliative gastrectomy. Moreover, since patients with better survival had an opportunity to receive additional chemotherapy, cycles of chemotherapy were not included in the survival analysis.

This was a retrospective real-world study; therefore, factors influencing medical decisions on SC or CO as first-line treatment were various and hard to completely control. Thus, several measures were taken to reduce bias. Appropriate inclusion and exclusion criteria were set to maximize the comparability between the groups and to enhance the simulation of the real decision-making situation. For instance, patients' general conditions are usually considered when deciding to perform surgery or not, and in the study, weaker patients with ECOG PS ≥2 were excluded. Moreover, the PSM and multivariate survival analyses were employed simultaneously to minimize the effects of confounding factors.

There are several limitations in the study. First, the second or end-line chemotherapy was not included for analysis, and progression-free survival was not evaluated as an endpoint for first-line treatment. However, the study objective was to investigate the OS benefit of first-line treatment strategy. Second, although other researches have demonstrated the safety of palliative gastrectomy, [@CIT0015] evaluation of postoperative complications, adverse events caused by chemotherapy, and the quality of life among the patients in the SC group should be performed in our study; the evaluation were limited because of a lack of information. Third, the sample sizes of some subgroups were too small to analyze, and the conclusions drawn from the subgroup analysis need to be validated in future studies with higher evidence levels.

In conclusion, the present study provided real-world evidence that palliative gastrectomy plus chemotherapy could improve survival in patients with mild or asymptomatic mGC compared with chemotherapy alone. Treatment factors, such as chemotherapy regimens and type of resection, might influence the survival benefit of palliative gastrectomy. Patients who received taxane-based regimens might be suitable for palliative gastrectomy.

We are grateful that this study was supported by National Key R&D Program of China (2018YFC1313300), Natural Science Foundation of Guangdong Province (2014A030312015), Science and Technology Program of Guangdong (2015B020232008), Science and Technology Program of Guangzhou (15570006, 201508020250, 201604020003).

Availability of data and materials {#S0005}
==================================

The key raw data have been deposited into the Research Data Deposit (<http://www.researchdata.org.cn>), with the Approval Number of RDDA2019001002 and the datasets used in this study are publicly available.

Disclosure {#S0006}
==========

Dr Rui-Hua Xu reports grants from National Key R&D Program of China, Natural Science Foundation of Guangdong Province, Science and Technology Program of Guangdong, and Science and Technology Program of Guangzhou, during the conduct of the study. The authors report no other conflicts of interest in this work.

[^1]: These authors contributed equally to this work

[^2]: **Notes:** ^a^Primary tumor location was defined by endoscopy or computed tomography (CT) findings. ^b^Metastatic lesion location was defined by CT/ultrasound imaging or intraoperative findings. ^c^The cutoff value for ratios of positive lymph nodes to total lymph nodes examined were determined by X-tile software 3.6.1 (Yale University, New Haven, CT, USA). ^d^*P*-value for comparison in characteristics between unmatched SC and CO groups.

    **Abbreviations:** CEA, carcinoembryonic antigen; NOS, not otherwise specified.
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